Tag Archive for: Immuno-oncology

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

/in

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive Directors Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up To support the acceleration of proof-of-concept cancer vaccine, ITOP1, into Phase I/IIa clinical development, to prevent the recurrence of oesophageal cancers Oxford, UK […]

Read more

Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025

/in

Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for […]

Read more

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

/in

Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion Experienced team with a background in biotechnology and company building led by co-CEO’s Michael Krohn and Lukas Linnig Paul Scholz, the principal inventor of G-dase E technology, joins […]

Read more

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

/in

Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]

Read more

NeoPhore appoints Michael Shih as Chief Executive Officer

/in

Highly experienced corporate development leader with a track record of international pharma and biotech deal-making New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as Chief Executive […]

Read more